Usefulness of Platelet-to-Lymphocyte Ratio to Predict Long-Term All-Cause Mortality in Patients at High Risk of Coronary Artery Disease Who Underwent Coronary Angiography
Overview
Authors
Affiliations
Platelet-to-lymphocyte ratio (PLR) has recently been studied as a biomarker in patients with established coronary artery disease (CAD). The association between PLR and long-term all-cause mortality is unclear in patients at high risk of CAD who undergo coronary angiography for various indications. Follow-up was completed for 514 patients who underwent coronary angiography in a prospective study cohort. The primary end point was all-cause mortality. Patients were classified into tertiles based on preangiography PLR and also dichotomized based on the optimal cutoff at a PLR of 137, determined from the receiver operating characteristic curve analysis. The mean follow-up period was 5.0 ± 1.3 years, with 50 all-cause deaths. On the Kaplan-Meier analysis, patients in Tertile 3 (PLR > 145) had worse prognosis than patients in Tertiles 1 (PLR ≤ 106) and 2 (PLR 106.1 to 145) (p = 0.0075), and patients with PLR ≥ 137 had a significantly higher rate of all-cause mortality than those with PLR < 137 (p = 0.0006). On multivariate Cox regression adjusting for known cardiovascular risk factors, PLR was a strong, independent predictor of long-term all-cause mortality on the tertile analysis (Tertile 3 vs Tertile 1: hazard ratio 2.52, 95% confidence interval 1.18 to 5.39, p = 0.017) and based on the cutoff at a PLR of 137 (PLR ≥ 137 vs <137: hazard ratio 2.25, 95% confidence interval 1.21 to 4.20, p = 0.011). In conclusion, elevated PLR is associated with long-term all-cause mortality in patients at high risk of CAD who undergo coronary angiography, and PLR may be a useful prognostic biomarker in this population.
Guo H, Li Y, Wang L Pediatr Surg Int. 2024; 40(1):191.
PMID: 39012349 DOI: 10.1007/s00383-024-05787-w.
Su N, Zheng Y, Zhang X, Tang X, Tang L, Wang Q BMC Nephrol. 2022; 23(1):415.
PMID: 36585653 PMC: 9803258. DOI: 10.1186/s12882-022-03038-5.
Russu E, Muresan A, Arbanasi E, Kaller R, Hosu I, Voidazan S J Clin Med. 2022; 11(9).
PMID: 35566745 PMC: 9103104. DOI: 10.3390/jcm11092620.
Urbanowicz T, Olasinska-Wisniewska A, Michalak M, Rodzki M, Witkowska A, Straburzynska-Migaj E Biology (Basel). 2022; 11(1).
PMID: 35053032 PMC: 8772913. DOI: 10.3390/biology11010034.
Clinical and Histopathological Factors Influencing IgA Nephropathy Outcome.
Konieczny A, Donizy P, Golebiowski T, Tukiendorf A, Halon A, Kusztal M Diagnostics (Basel). 2021; 11(10).
PMID: 34679462 PMC: 8534654. DOI: 10.3390/diagnostics11101764.